SML0042
Lazabemide hydrate
≥97% (HPLC)
Synonym(s):
N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide hydrate, Ro 19-6327 hydrate
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C8H10ClN3O · xH2O
CAS Number:
Molecular Weight:
199.64 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Product Name
Lazabemide hydrate, ≥97% (HPLC)
InChI
1S/C8H10ClN3O.H2O/c9-6-1-2-7(12-5-6)8(13)11-4-3-10;/h1-2,5H,3-4,10H2,(H,11,13);1H2
SMILES string
O.NCCNC(=O)c1ccc(Cl)cn1
InChI key
JYWYNPKXSLPWGV-UHFFFAOYSA-N
assay
≥97% (HPLC)
form
powder
storage condition
desiccated
color
white to tan
solubility
DMSO: ≥22 mg/mL
originator
Roche
storage temp.
room temp
Quality Level
Related Categories
Application
Lazabemide hydrate may be used in cell signaling studies.
Biochem/physiol Actions
Lazabemide is a selective and reversible monoamine oxidase B (MAO-B) inhibitor and Anti-Parkinson. Also it inhibits monoamine uptake at high concentrations (IC50 values are 86, 123 and > 500 μM for noradrenalin, serotonin and dopamine uptake respectively).
Lazabemide is effective in treatment of Alzheimer′s disease and in combination with nicotine replacement therapy aids in smoking cessation.
Selective MAO-B inhibitor; Antiparkinson
Features and Benefits
This compound is featured on the Dopamine and Norepinephrine Metabolism and Histamine Synthesis and Metabolism pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Lazabemide for the treatment of Alzheimer's disease: rationale and therapeutic perspectives.
A M Cesura et al.
Advances in neurology, 80, 521-528 (1999-07-20)
R Raddatz et al.
The Journal of pharmacology and experimental therapeutics, 292(3), 1135-1145 (2000-02-25)
A series of phenoxy-substituted methylimidazoline derivatives were synthesized and used to define the ligand recognition properties of the imidazoline-binding domain (IBD) on monoamine oxidase (MAO)-B and its role in substrate processing. The rank order of potency for selected compounds in
Andrzej Dekundy et al.
Journal of neural transmission (Vienna, Austria : 1996), 118(12), 1703-1716 (2010-12-17)
Subtype 5 metabotropic glutamate receptors (mGluR5) are abundant in the basal ganglia, amygdala, septum, hippocampus, peripheral sensory neurones and dorsal horn of the spinal cord. Thus, mGluR5 has been implicated in central processes underlying movement control, emotion, learning, and nociception.
Clinical trials of neuroprotection for Parkinson's disease.
Peter A LeWitt
Neurology, 63(7 Suppl 2), S23-S31 (2004-10-13)
Glaucia H Braun et al.
Journal of biomolecular structure & dynamics, 25(4), 347-355 (2007-12-21)
Monoamine oxidase is a flavoenzyme bound to the mitochondrial outer membranes of the cells, which is responsible for the oxidative deamination of neurotransmitter and dietary amines. It has two distinct isozymic forms, designated MAO-A and MAO-B, each displaying different substrate
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service